Previous close | 0.5000 |
Open | 0.6100 |
Bid | 0.0000 |
Ask | 0.9500 |
Strike | 6.00 |
Expiry date | 2024-06-07 |
Day's range | 0.5000 - 0.6100 |
Contract range | N/A |
Volume | |
Open interest | 12 |
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Erick Lucera, the EVP, Chief Financial Officer of Editas Medicine Inc (NASDAQ:EDIT), sold 22,337 shares of the company on May 20, 2024. Following this transaction, the insider has a total of 116,829 shares remaining in the company. Editas Medicine Inc is a biotechnology company focused on developing transformative gene editing therapies to treat a broad range of diseases.
On May 13, 2024, Jessica Hopfield, Director at Editas Medicine Inc (NASDAQ:EDIT), purchased 45,000 shares of the company, as reported in the SEC Filing. Editas Medicine Inc (NASDAQ:EDIT) is a biotechnology company focused on developing transformative gene editing therapies to treat a broad range of diseases. Over the past year, the insider transaction history at Editas Medicine Inc shows a trend with 1 insider buy and 11 insider sells.